BLC
GMAB icon

Brown, Lisle/Cummings’s Genmab GMAB Stock Holding History

Brown, Lisle/Cummings’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.87K Sell
68
-9
-12% -$239 ﹤0.01% 864
2026
Q1 		$2.07K Buy
+77
New +$2.31K ﹤0.01% 814

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Brown, Lisle/Cummings's GMAB Position: Q2 2026 in Review

Brown, Lisle/Cummings reduced its Genmab (GMAB) stake by 12% in Q2 2026, selling an estimated $239 and leaving 68 shares worth $1.87K. The position accounts for ﹤0.01% of the portfolio, ranked #864.

Brown, Lisle/Cummings first reported a position in GMAB in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.07K in Q1 2026. 291 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Brown, Lisle/Cummings held 68 shares of Genmab worth $1.87K as of Q2 2026.
  • Brown, Lisle/Cummings sold 9 Genmab shares in Q2 2026, an estimated $239.
  • Genmab made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q2 2026, its #864 holding.
  • Brown, Lisle/Cummings first reported a position in Genmab in Q1 2026 and has held it in 2 quarters since.
  • Brown, Lisle/Cummings's Genmab position peaked at $2.07K in Q1 2026.
  • 291 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q2 2026, filed 2 Sep 2026.